Mutations and thrombosis in essential thrombocythemia
Paola Guglielmelli(Tumour Institute of Tuscany), Ayalew Tefferi(Mayo Clinic in Arizona), Benedetta Sordi(Azienda Ospedaliero-Universitaria Careggi), Animesh Pardanani(Palmetto Hematology Oncology), Giacomo Coltro(Azienda Ospedaliero-Universitaria Careggi), Alessandro M. Vannucchi(University of Florence), Giuseppe Gaetano Loscocco(Azienda Ospedaliero-Universitaria Careggi), Natasha Szuber(Mayo Clinic in Arizona), Christy M. Finke(Mayo Clinic), Erika Morsia(Marche Polytechnic University), Naseema Gangat(Mayo Clinic), Curtis A. Hanson(Mayo Clinic), Terra L. Lasho(Mayo Clinic)
Cited by 41
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735